Targeted approach to asbestos-related cancer

A new cancer treatment for asbestos-related target showed promise in animal form. Test results, reported in the open access journal BMC Cancer, increasing hopes of new treatments for this deadly cancer.

Malignant tumor (MMs) is a rare type of cancer, most commonly as a result of asbestos exposure. It tends to diagnose decades after exposure, so seldom are caught early. Current treatments, which include surgery, chemotherapy, and restricted the effectiveness and unpleasant side effects.

Traditional chemotherapy drugs do the job by eliminating cells that divide quickly. As a result, they're murderers, elimination of dividing healthy cells, including those in the bone marrow and digestive tract and hair follicles as well as cancer cells. The result is that unwanted mixture of side effects, including a weakened immune system, digestive difficulties and hairloss. The end is sought target therapies designed to kill cancer cells and maintain healthy tissue unharmed, yet. New target therapy is silica, covered in antibodies that recognize a protein created by cancer cells in large quantities. When injected into microparticles mouse model of cancer, helps the body microparticles link cells of tumors, where they are able to release their cargo pants concealed – drug doxorubicin chemotherapy then.

New treatment is more effective and less toxic than doxorubicin alone, Brock TD Mosman and colleagues report. Shrinking tumors and cancerous cells have spread much less animals were largely able to keep the weight and health through treatment. Overall, the data indicate that the targeted therapy may be best for chemotherapy alone.